Cargando…

Decentralized clinical trials (DCTs): A few ethical considerations

Decentralized clinical trials (DCTs) are studies in which the need for patients to physically access hospital-based trial sites is reduced or eliminated. The CoViD-19 pandemic has caused a significant increase in DCT: a survey shows that 76% of pharmaceutical companies, device manufacturers, and Con...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrini, Carlo, Mannelli, Chiara, Riva, Luciana, Gainotti, Sabina, Gussoni, Gualberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797802/
https://www.ncbi.nlm.nih.gov/pubmed/36590004
http://dx.doi.org/10.3389/fpubh.2022.1081150
_version_ 1784860762215284736
author Petrini, Carlo
Mannelli, Chiara
Riva, Luciana
Gainotti, Sabina
Gussoni, Gualberto
author_facet Petrini, Carlo
Mannelli, Chiara
Riva, Luciana
Gainotti, Sabina
Gussoni, Gualberto
author_sort Petrini, Carlo
collection PubMed
description Decentralized clinical trials (DCTs) are studies in which the need for patients to physically access hospital-based trial sites is reduced or eliminated. The CoViD-19 pandemic has caused a significant increase in DCT: a survey shows that 76% of pharmaceutical companies, device manufacturers, and Contract Research Organizations adopted decentralized techniques during the early phase of the pandemic. The implementation of DCTs relies on the use of digital tools such as e-consent, apps, wearable devices, Electronic Patient-Reported Outcomes (ePRO), telemedicine, as well as on moving trial activities to the patient's home (e.g., drug delivery) or to local healthcare settings (i.e., community-based diagnosis and care facilities). DCTs adapt to patients' routines, allow patients to participate regardless of where they live by removing logistical barriers, offer better access to the study and the investigational product, and permit the inclusion of more diverse and more representative populations. The feasibility and quality of DCTs depends on several requirements including dedicated infrastructures and staff, an adequate regulatory framework, and partnerships between research sites, patients and sponsors. The evaluation of Ethics Committees (ECs) is crucial to the process of innovating and digitalizing clinical trials: adequate assessment tools and a suitable regulatory framework are needed for evaluation by ECs. DCTs also raise issues, many of which are of considerable ethical significance. These include the implications for the relationship between patients and healthcare staff, for the social dimension of the patient, for data integrity (at the source, during transmission, in the analysis phase), for personal data protection, and for the possible risks to health and safety. Despite their considerable growth, DCTs have only received little attention from bioethicists. This paper offers a review on some ethical implications and requirements of DCTs in order to encourage further ethical reflection on this rapidly emerging field.
format Online
Article
Text
id pubmed-9797802
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97978022022-12-30 Decentralized clinical trials (DCTs): A few ethical considerations Petrini, Carlo Mannelli, Chiara Riva, Luciana Gainotti, Sabina Gussoni, Gualberto Front Public Health Public Health Decentralized clinical trials (DCTs) are studies in which the need for patients to physically access hospital-based trial sites is reduced or eliminated. The CoViD-19 pandemic has caused a significant increase in DCT: a survey shows that 76% of pharmaceutical companies, device manufacturers, and Contract Research Organizations adopted decentralized techniques during the early phase of the pandemic. The implementation of DCTs relies on the use of digital tools such as e-consent, apps, wearable devices, Electronic Patient-Reported Outcomes (ePRO), telemedicine, as well as on moving trial activities to the patient's home (e.g., drug delivery) or to local healthcare settings (i.e., community-based diagnosis and care facilities). DCTs adapt to patients' routines, allow patients to participate regardless of where they live by removing logistical barriers, offer better access to the study and the investigational product, and permit the inclusion of more diverse and more representative populations. The feasibility and quality of DCTs depends on several requirements including dedicated infrastructures and staff, an adequate regulatory framework, and partnerships between research sites, patients and sponsors. The evaluation of Ethics Committees (ECs) is crucial to the process of innovating and digitalizing clinical trials: adequate assessment tools and a suitable regulatory framework are needed for evaluation by ECs. DCTs also raise issues, many of which are of considerable ethical significance. These include the implications for the relationship between patients and healthcare staff, for the social dimension of the patient, for data integrity (at the source, during transmission, in the analysis phase), for personal data protection, and for the possible risks to health and safety. Despite their considerable growth, DCTs have only received little attention from bioethicists. This paper offers a review on some ethical implications and requirements of DCTs in order to encourage further ethical reflection on this rapidly emerging field. Frontiers Media S.A. 2022-12-15 /pmc/articles/PMC9797802/ /pubmed/36590004 http://dx.doi.org/10.3389/fpubh.2022.1081150 Text en Copyright © 2022 Petrini, Mannelli, Riva, Gainotti and Gussoni. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Petrini, Carlo
Mannelli, Chiara
Riva, Luciana
Gainotti, Sabina
Gussoni, Gualberto
Decentralized clinical trials (DCTs): A few ethical considerations
title Decentralized clinical trials (DCTs): A few ethical considerations
title_full Decentralized clinical trials (DCTs): A few ethical considerations
title_fullStr Decentralized clinical trials (DCTs): A few ethical considerations
title_full_unstemmed Decentralized clinical trials (DCTs): A few ethical considerations
title_short Decentralized clinical trials (DCTs): A few ethical considerations
title_sort decentralized clinical trials (dcts): a few ethical considerations
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797802/
https://www.ncbi.nlm.nih.gov/pubmed/36590004
http://dx.doi.org/10.3389/fpubh.2022.1081150
work_keys_str_mv AT petrinicarlo decentralizedclinicaltrialsdctsafewethicalconsiderations
AT mannellichiara decentralizedclinicaltrialsdctsafewethicalconsiderations
AT rivaluciana decentralizedclinicaltrialsdctsafewethicalconsiderations
AT gainottisabina decentralizedclinicaltrialsdctsafewethicalconsiderations
AT gussonigualberto decentralizedclinicaltrialsdctsafewethicalconsiderations